Tytuł artykułu
Autorzy
Wybrane pełne teksty z tego czasopisma
Identyfikatory
Warianty tytułu
Ligands of gaba-ergic receptors : the structure, properties and therapeutic prospects
Języki publikacji
Abstrakty
This review attempts to briefly summarize the recent development in the study of ?-aminobutyric (GABA) receptors, and their ligands. The search on compounds with agonistic and antagonistic properties of GABA receptors, the structure activity relationships, and therapeutic prospects of GABA receptors ligands was also described. GABA is the major inhibitory neurotransmitter in the brain [1-6], and influences neurons via a large number of receptor subtypes which are grouped on the basis of their pharmacology under three major classes of receptors: GABAA, GABAB, and GABAC. GABAA and GABAC receptors are ligand gated ion channels, while GABAB receptors are G-protein coupled receptors [7-10]. These receptors, especially GABAA receptors, are involved in neurological and psychiatric disorders, and are therapeutic targets in certain diseases. Several different binding sites on GABAA receptors were proposed, these include agonist sites [11-14], which also recognize competitive antagonists [15], and many positive or negative modulators sites [16-20]. GABAA receptors are modulated by benzodiazepines [21-26], barbiturates, neurosteroides [27], klomethiazol [28, 29], anesthetics [30-33], ethanol [34], some insecticides [35], furosemide [36], Zn2+ iones [37], and sites for other compounds [38-40]. Some ligands of GABAB and GABAC receptors are also presented [41-44].
Wydawca
Czasopismo
Rocznik
Tom
Strony
571--598
Opis fizyczny
Bibliogr. 53 poz., schem.
Twórcy
autor
- Katedra Chemii Farmaceutycznej Collegium Medicum Uniwersytetu Jagiellońskiego, ul. Medyczna 9, 30-688 Kraków
autor
- Katedra Chemii Farmaceutycznej Collegium Medicum Uniwersytetu Jagiellońskiego, ul. Medyczna 9, 30-688 Kraków
Bibliografia
- [1] S. Konturek, Fizjologia człowieka, t. I. Fizjologia ogólna., Wyd. VI, Fundacja dla Wydziału Lekarskiego UJ, Kraków 1995.
- [2] W. Kostowski, Farmakologia. Podstawy farmakoterapii., Wydawnictwo Lekarskie PZWL, Warszawa 1998,2001.
- [3] E. Roberts, GABA in nervous system function. Raven Press, New York, 1976.
- [4] B. Malawska, Wiad. Chem., 1989, 43,457.
- [5] P. Krogsgaard-Larsen, B. Frølund, F. S. Jørgensen, A. Schousboe, J. Med. Chem. 1994,37, 2489.
- [6] J.Z. Nowak, J.B. Zawilska, (red), Receptory - struktura, charakterystyka, funkcja. PWN, Warszawa, 1997.
- [7] L. Coyne, G. Lees, Curr. Anaesth. Crit. Care, 2002,13, 334.
- [8] M. Chebib, G.A.R. Johnston, J. Med. Chem., 2000,43, 1428.
- [9] L Bohme, H. Luddens, Curr. Med. Chem., 2001,8, 1258.
- [10] A. Zejc, M. Gorczyca Chemia lekó, Wydawnictwo Lekarskie PZWL, Warszawa 2002.
- [11] E.R. Korpi, R.M. Mihalek, S.T. Sinkkonen, B. Hauer, W. Hevers, G.E. Homanics, W. Sieghart, H. Luddens, Neuroscience, 2002,109,733.
- [12] E. Sigel, R.H. Dodd, Drugs Fut., 2001,26, 1191.
- [13] E. Sanna, F. Busonero, G. Talani, M. Carta, F. Massa, M. Peis, E. Maciocco, G. Biggio, Eur. J. Pharmacol., 2002,451, 103.
- [14] P.R. Carlier, E.S.-H. Chow, R.L. Barlow, J.R. Bloomquist, Biooig. Med. Chem. Lett., 2002, 12, 1985.
- [15] B. Frølund, L. Tagmose, A. T. Jørgensen, U. Kristiansen, T. B. Stensb0l, T. Liljefors, P. Krogsgaard-Larsen, Eur. J. Med. Chem., 2003, 38,447.
- [16] X.-L. Ju, Y. Ozoe, bioorg. Med. Chem., 2000, 8,2337.
- [17] D.I. Obradovič, D.R. Bokonjič, M.M. Savič, D.S. Andjelkovič, N.D. Ugrešič, M.R Stojilkovič, Pharmacol. Res., 2002,46, 149.
- [ 18] D.J. Canney K.D. Holland, J.A. Levine, A.C. McKeon, J.A. Ferrendelli, D.R Covey, I. Med. Chem., 1991,34,1460.
- [19] E.M. Petersen, K. Xu, K.D. Holland, A.C. McKean, S.M. Rothman, J.A. Ferrendelli, D.F. Covey, J. Med. Chem., 1994,37,275.
- [20] D.J. Canney, H.-F. Lu, A.C. McKeoan, K.-W. Yoon, K. Xu, K.D. Holland, S.M. Rothman, J.A. Ferrendelli, D.F. Covey, Bioorg. Med. Chem., 1998, 6, 43.
- [21] L.A. Sorbera, P.A. Leeson, J. Silvestre, J. Castaner, Drugs Fut., 2001,26, 651.
- [22] Q. Wang, Y. Han, H. Xue, CNS Drug Rev., 1999,5, 125.
- [23] S. Selleri, F. Bruni, C. Costagli, A. Costanzo, G. Guerrini, G. Ciciani, P. Gratteri, C. Bonaccini, P. Malmberg Aiello, F. Besnard, S. Renard, B. Costa, C. Martini, J. Med. Chem., 2003,46,310.
- [24] M.S. Chambers, J.R. Atack, F.A. Bromidge, H.B. Brughton, S. Cook, G.R. Dawson, S.C Hobbs, K.A. Maubach, A.J.Reeve, G.R.Seabrook, K. Wafford, A.M. MacLeod, J. Med. Chem., 2002,45, 1176.
- [25] P.A. Albaugh, L. Marshal, J. Gregory, G. White, A. Hutchison, P.C. Ross, D. W. Gallagher, J.F. Tallman, M. Crago, J.V. Casella, J. Med. Chem., 2002,45, 5043.
- [26] T. Akbarzadeh, S.A. Tabatabi, M.J. Khoshnoud, J. Mohammad, B. Shafaghi, A. Shafiee, Bioorg. Med. Chem., 2003,11, 769.
- [27] I. Collins, Ch. Moyes, W.B. Davey, M. Rowley, F.A. Bromidge K. Quirk, J.R. Atack, R.M. Mckernan, S.-A. Thompson, K. Wafford, G.R. Dawson, A. Pike, B. Sohal, N.N. Tsou, R.G. Ball, J.L. Castro, J. Med. Chem., 2002,45, 1887.
- [28] X. Li, Ch. Zhang, R. Furtmueller, K. Fuchs, S. Huck, W. Sieghart, J. Deschamps, J.M. Cook, J. Med. Chem., 2003,46, 5567.
- [29] P. Kahnberg, E. Lager, C. Rosenberg, J. Schougaard, L. Camet, O. Sterner, E.0. Nielsen, M. Nielsen, T. Liljefors, J. Med. Chem., 2002,45,4188.
- [30] M.S. Huen, K.-M. Hui, J.W.C. Leung, E. Sigel, R. Baur, J.T.-F. Wong, Biochem. Pharmacol., 2003, 66, 2397.
- [31] K.-M. Hui, M.S. Huen, H. Y. Wang, H. Zheng, E. Sigel, R. Baur, H. Ren, Z. Wang Li, J.T.-F. Wong, H. Xue, Biochem. Pharmacol., 2002, 64, 1415.
- [32] M. Vergnes, A. Boehrer, Xiaohui He, H. Greney, M. Dontenwill, J. Cook, C. Marescaux, Epilepsy Res., 2001,47,43.
- [33] J.F. Navarro, E. Buron, M. Martin-Lopez, Progr. Neuro-Psychopharmacol. Biol. Psychiatry, 2002, 26 1389.
- [34] F. Crestani, R. Assandri, M. Tauber, J. R. Martin, U. Rudolph, Neuropharmacology, 2002,43,679.
- [35] W. Wang, D.-Ch. Wu, Y.-H. Chen, W. He, L.-Ch. Yu, Brain Res., 2002,956,393.
- [36] R. Rupprecht, Psychoneuroendocrin., 2003,28,139.
- [37] P. Yang, B. L. Jones, L. P. Henderson, Neuropharmacology, 2002,43, 619.
- [38] R.M. Nelson, A.H. Hainsworth, D.G. Lambert, J.A. Jones, T.K. Murray, D.A. Richards, J. Gabrielsson, A.J. Cross, A.R. Green, Neuropharmacology, 2001, 41, 159.
- [39] R.M. Nelson, A.R. Green, A.H. Hainsworth, Eur. J. Pharmacol., 2002, 452,255.
- [40] S.M. O’Shea, L.C. Wong, N.L. Harrison, Brain Res., 2000,852, 344.
- [41] A. Anderson, D. Belelli, D.J. Bennett, K.I. Buchanan, A. Casula, A. Cooke, H. Feilden, David K. Ge„ell, N.M. Hamilton. E.J. Hutchinson, J.J. Lambert, M.S. Maidment, R. McGuire, P. McPhail, S. Miller, A. Muntoni, J.A. Peters, F.H. Sansbury, D. Stevenson, H. Sundaram, J. Med. Chem., 2001,44, 3582.
- [42] B.D. Harris, E.J. Moody, P. Skolnick, Eur. J. Pharmacol., 1998,341,349.
- [43] T.P. Piepponen, K. Kiianmaa, L. Ahtee, Pharmacol. Biochem. Behav., 2002, 74, 21.
- [44] C. Vale, E. Fonfria, J. Bujons, A. Messeguer, E. Rodriguez-Farre, C. Sunol, Neuroscience, 2003, 117,397.
- [45] A. Guyon, L. Cathala, D. Paupardin-Tritsch, D. Eugene, Neuropharmacology, 2002,43, 750.
- [46] A. Barberis, E.M. Petrini, E. Cherubini, J. W. Mozrzymas, Neuropharmacology, 2002, 43, 607.
- [47] C.M. van Rijn, E. Willems-van Bree, Eur. J. Pharmacol., 2003,464, 95.
- [48] N. Rezai, C. Duggan, D. Cairns, G. Lees, P. L. Chazot, Biochem. Pharmacol., 2003, 65, 619.
- [49] G. Lees, P.L. Chazot, H. Vankayalapati, G. Singh, Bioorg. Med. Chem. Lett., 2000,10, 1759.
- [50] F. Wang, J. Li, Ch. Wu, J. Yang, F. Xu, Q. Zhao, Pharmacol. Biochem. Behavior., 2003, 74, 573.
- [51] H. Mohler, D. Benke, J.-M. Fritschy, Life Sei., 2001, 68,2297.
- [52] P.V. Dicpinigatis, Pulmon. Pharmacol. Ther., 1999,12, 257.
- [53] M.S. Cousins, D.C.S. Roberts, H. de Wit, Drug Alcohol Dependence, 2002,65,209.
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-article-BUS2-0006-0033